News for Healthier Living

Patients With Moderate-to-Severe Ulcerative Colitis May Find Significant Relief as New Treatment Option Shows Good Results in Clinical Trial

A phase 2 trial of a monoclonal antibody known as tulisokibart for moderate-to-severe ulcerative colitis (UC) showed promising results for those who have not responded to conventional inflammatory bowel disease (IBD) treatment. The results were reported Thursday, September 26, in The New England Journal of Medicine.

September 25, 2024


October 5 2024

October 4 2024

October 3 2024

October 2 2024

October 1 2024

September 30 2024

September 29 2024

September 28 2024

September 27 2024

September 26 2024

September 25 2024

September 24 2024

September 23 2024

September 22 2024

September 21 2024